China coronavirus: cases surge as official admits human to human transmission

Parry, Jane

doi:10.1136/bmj.m236

Cited by 116 publications

(84 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 2019-nCoV is a novel coronavirus, which is different from SARS and other SARS-like viruses (3). However the time-varying transmission dynamics of NCP during the epidemic remain unclear (22). In this study, we estimated the R0 of NCP infected with 2019-nCoV nationwide, and found that the R0 was 4.5, which means an average of 4.5 secondary cases generated by a primary case in the early stage.…”

Section: Discussionmentioning

confidence: 88%

Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China

Liu

Xiao

et al. 2020

Preprint

274

228

View full text Add to dashboard Cite

Rationale: Several studies have estimated basic production number of novel coronavirus pneumonia (NCP). However, the time-varying transmission dynamics of NCP during the outbreak remain unclear. Objectives: We aimed to estimate the basic and time-varying transmission dynamics of NCP across China, and compared them with SARS. Methods: Data on NCP cases by February 7, 2020 were collected from epidemiological investigations or official websites. Data on severe acute respiratory syndrome (SARS) cases in Guangdong Province, Beijing and Hong Kong during 2002-2003 were also obtained. We estimated the doubling time, basic reproduction number (R0) and time-varying reproduction number (Rt) of NCP and SARS. Measurements and main results: As of February 7, 2020, 34,598 NCP cases were identified in China, and daily confirmed cases decreased after February 4. The doubling time of NCP nationwide was 2.4 days which was shorter than that of SARS in Guangdong (14.3 days), Hong Kong (5.7 days) and Beijing (12.4 days). The R0 of NCP cases nationwide and in Wuhan were 4.5 and 4.4 respectively, which were higher than R0 of SARS in Guangdong (R0=2.3), Hongkong (R0=2.3), and Beijing (R0=2.6). The Rt for NCP continuously decreased especially after January 16 nationwide and in Wuhan. The R0 for secondary NCP cases in Guangdong was 0.6, and the Rt values were less than 1 during the epidemic. Conclusions:NCP may have a higher transmissibility than SARS, and the efforts of containing the outbreak are effective.However, the efforts are needed to persist in for reducing time-varying reproduction number below one. now named as Novel Coronavirus Pneumonia (NCP), occurred in Wuhan, Hubei Province, China. The disease has rapidly spread from Wuhan to other areas. As a novel virus, the time-varying transmission dynamics of NCP remain unclear, and it is also important to compare it with SARS.What This Study Adds to the Field: We compared the transmission dynamics of NCP with SARS, and found that NCP has a higher transmissibility than SARS. Time-varying production number indicates that rigorous control measures taken by governments are effective across China, and persistent efforts are needed to be taken for reducing instantaneous reproduction number below one. author/funder. All rights reserved. No reuse allowed without permission.

show abstract

Section: Discussionmentioning

confidence: 88%

Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China

Liu

Xiao

et al. 2020

Preprint

274

228

View full text Add to dashboard Cite

show abstract

“…The human to the human spreading of the virus occurs due to close contact with an infected person, exposed to coughing, sneezing, respiratory droplets or aerosols. These aerosols can penetrate the human body (lungs) via inhalation through the nose or mouth (Fig 2) ( [11][12][13][14].…”

Section: Comparative Analysis Of Emergence and Spreading Of Coronavirmentioning

confidence: 99%

COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses

Shereen

Khan

Kazmi

et al. 2020

Journal of Advanced Research

3,514

2,878

View full text Add to dashboard Cite

The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak. glycoprotein of novel coronavirus is developed from a SARS-CoV (CoVZXC21 or CoVZC45) and a yet unknown . Nonetheless, to eradicate the virus, more work is required to

show abstract

“…As of 7 pm Central European Time on 24 March, 2020, 407,485 cases of pneumonia had been reported globally [1,2,3] that were caused by the novel coronavirus that is now known as COVID-19 [4]. 18,227 cases have resulted in death [5]. There have been 325,894 reported cases in other 184 countries and territories, including Italy (n=69,176), Iran (n=24,811) and South Korea (n=9,037) [6,7].…”

Section: Introductionmentioning

confidence: 99%